Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

Next Previous
Trial Profile

Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Lenalidomide (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms LENAGEM-PANC

Most Recent Events

  • 26 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 30 Jun 2012 Company added in the association field as reported by EudraCT.
  • 02 Mar 2012 Additional lead trial centres, lead trial investigators and Celgene Corporation as company identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top